# Intellia Therapeutics (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/intellia-therapeutics-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 44 |
| Citations | 48,910 |
| City | Cambridge |
| Country | United States |
| Description | Intellia Therapeutics (United States) is a research organisation in Cambridge, United States. OpenAlex records 99 works and 48,910 citations for it. 1 researchers list it as their most recent affiliation. |
| Homepage | https://www.intelliatx.com/ |
| OpenAlex ID | https://openalex.org/I4210131291 |
| Region | Massachusetts |
| Researchers | 1 |
| ROR ID | https://ror.org/03b368668 |
| Type | company |
| Works | 99 |

## University papers

- [Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia](https://scholariq.org/papers/tisagenlecleucel-in-children-and-young-adults-with-b-cell-lymphoblastic-leukemia/)
- [Everolimus for Advanced Pancreatic Neuroendocrine Tumors](https://scholariq.org/papers/everolimus-for-advanced-pancreatic-neuroendocrine-tumors/)
- [Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/everolimus-plus-octreotide-long-acting-repeatable-for-the-treatment-of-advanced/)
- [Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/everolimus-for-angiomyolipoma-associated-with-tuberous-sclerosis-complex-or/)
- [Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial](https://scholariq.org/papers/daily-oral-everolimus-activity-in-patients-with-metastatic-pancreatic/)

## University researchers

- [David Lebwohl](https://scholariq.org/researchers/david-lebwohl/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.